Long acting GLP-1 receptor agonist (injectable)
Semaglutide 0.5 mg subcutaneous once weekly
SEMA_SC_0p5MG_QW
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 2.0 mg subcutaneous once weekly
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.99 (-1.37 to -0.61) | 0.54 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.19 (-1.62 to -0.75) | 0.77 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.01 (-0.43 to 0.44) | 0.51 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.44 (-2.09 to -0.66) | 0.67 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.95 (-1.46 to -0.41) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.34 (-1.91 to -0.67) | 0.81 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.79 (-4.04 to -1.55) | 0.70 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.84 (-4.00 to 0.91) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.60 (-4.28 to -0.95) | 0.81 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.73 (-6.95 to 2.16) | 0.72 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.24 (-4.57 to -1.72) | 0.88 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.19 (-6.58 to 2.83) | 0.56 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.26 (-7.04 to 2.71) | 0.77 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.61 (0.23 to 1.83) | 0.53 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 7.12 (1.33 to 26.82) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.03 (0.00 to 0.43) | 0.84 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.41 (0.01 to 10.73) | 0.72 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.54 (0.21 to 1.33) | 0.67 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.38 (-4.10 to -0.56) | 0.53 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.28 (-1.86 to 8.49) | 0.48 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.46 (-6.20 to 2.99) | 0.41 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -4.08 (-8.14 to 0.10) | 0.64 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Placebo | MD -0.92 (-12.17 to 10.48) | 0.45 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.91 (0.44 to 10.05) | 0.47 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide 1.0 mg subcutaneous once weekly | OR 0.48 (0.20 to 1.61) | 0.61 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.30 (-0.01 to 2.62) | 0.92 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.56 (-0.79 to 1.99) | 0.40 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.99 (0.83 to 1.21) | 0.48 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.67 (1.04 to 2.72) | 0.49 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.84 (2.22 to 3.61) | 0.48 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.32 (1.69 to 3.14) | 0.56 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.86 (1.51 to 2.34) | 0.43 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.88 (1.37 to 2.68) | 0.45 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.71 (1.19 to 6.38) | 0.41 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 2.96 (0.36 to 28.50) | 0.30 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.26 (0.02 to 2.14) | 0.73 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 2.05 (0.94 to 5.14) | 0.29 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.34 (0.03 to 3.33) | 0.70 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 0.98 (0.11 to 6.27) | 0.57 |
| Alcohol use disorder | Serious adverse events | longest follow-up | Placebo | HR 0.55 (0.01 to 41.43) | 0.63 |
| Alcohol use disorder | Nausea | longest follow-up | Placebo | HR 6.14 (1.12 to 27.60) | 0.10 |
| Alcohol use disorder | Vomiting | longest follow-up | Placebo | HR 0.65 (0.07 to 4.88) | 0.78 |
Trials
- S00342679 randomized · 24 weeks
- NCT06896981Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial2025 · 31 randomized · 16 weeks
- NCT05520775Human Laboratory Screening of Semaglutide for Alcohol Use Disorder2022 · 48 randomized · 9 weeks
- S0029462020 · 32 randomized · 26 weeks
- SUSTAINEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial2017 · 868 randomized · 30 weeks
- SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes2016 · 1,201 randomized · 40 weeks
- SUSTAIN™Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes2014 · 308 randomized · 30 weeks
- SUSTAIN™ 5Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes2014 · 397 randomized · 30 weeks
- SUSTAIN™ 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes2014 · 1,089 randomized · 30 weeks
- SUSTAIN™Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy2014 · 601 randomized · 56 weeks
- SUSTAIN™1Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes2014 · 388 randomized · 30 weeks
- SUSTAIN™ 6A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)2013 · 3,297 randomized · 104 weeks
- SUSTAIN™ 2Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)2013 · 1,231 randomized · 56 weeks